GHRH (Growth Hormone Releasing Hormone)
GHRH is a 44-amino acid endogenous hypothalamic peptide that stimulates pulsatile growth hormone release from the anterior pituitary. It is the primary physiological regulator of GH secretion and the parent molecule from which synthetic analogues like sermorelin and CJC-1295 are derived.
Overview
GHRH was first isolated and characterized in 1982 by two independent groups — Guillemin et al. and Rivier et al. — from pancreatic tumors causing acromegaly, and subsequently from hypothalamic tissue. The discovery revealed the primary mechanism by which the hypothalamus controls growth hormone secretion and earned Roger Guillemin the extension of his Nobel Prize legacy in neuroendocrine regulation.
GHRH acts in concert with somatostatin (which inhibits GH release) and ghrelin (which amplifies GH release via a separate receptor) to produce the characteristic pulsatile pattern of GH secretion. This pulsatility is critical — continuous GH exposure produces different biological effects than pulsatile release, and maintaining physiological pulse patterns is a key rationale for using GHRH analogues rather than exogenous GH.
The native GHRH(1-44) molecule is rapidly degraded in circulation by dipeptidyl peptidase-IV (DPP-IV), which cleaves the N-terminal Tyr-Ala dipeptide, inactivating the molecule within minutes. This rapid degradation drove the development of modified analogues with improved pharmacokinetic profiles.
Mechanism of Action
GHRH binds to the GHRH receptor (GHRH-R), a G protein-coupled receptor (GPCR) expressed primarily on somatotroph cells in the anterior pituitary. Receptor activation triggers:
- Gαs coupling → cAMP/PKA pathway: GHRH-R activates adenylyl cyclase, increasing intracellular cAMP, which activates protein kinase A (PKA). This stimulates both GH gene transcription and GH vesicle exocytosis.
- Calcium influx: PKA phosphorylates L-type calcium channels, increasing intracellular Ca²⁺ which triggers GH granule release.
- Pit-1 transcription factor: GHRH signaling through cAMP/PKA activates Pit-1 (POU1F1), the master transcription factor for GH gene expression, somatotroph differentiation, and GHRH-R expression itself — creating a positive feedback loop.
- Somatotroph proliferation: Chronic GHRH signaling promotes somatotroph cell proliferation, increasing pituitary GH secretory capacity. This is why GHRH agonists upregulate receptor expression rather than causing desensitization.
Pulsatile Release Pattern
GHRH is released in a pulsatile fashion, primarily during sleep (particularly slow-wave sleep). The interaction between GHRH and somatostatin creates the characteristic GH pulse pattern:
- GHRH pulses → GH secretion bursts
- Somatostatin withdrawal → permissive windows for GH release
- Ghrelin amplification → enhanced GH pulse amplitude during GHRH stimulation
- GH and IGF-1 feedback → negative feedback suppressing GHRH release
Reconstitution Calculator
Research
GH Axis Regulation and Pulsatility
The discovery of GHRH established the hypothalamic-pituitary GH axis model. GHRH works in opposition to somatostatin (SRIF) — GHRH stimulates while somatostatin inhibits GH release. The alternating dominance of these signals creates GH pulses every 2-3 hours, with the largest pulses occurring during deep sleep (Veldhuis et al., 1995).
The addition of ghrelin/GHS-R1a signaling (discovered in 1999) completed the tripartite model of GH regulation. Ghrelin amplifies GHRH-stimulated GH release and can independently trigger GH pulses, explaining why GH secretagogues (ipamorelin, GHRP-2, MK-677) synergize with GHRH analogues.
Cardiac Repair and Cardioprotection
GHRH receptors are expressed on cardiomyocytes, and GHRH agonists have shown remarkable cardioprotective effects independent of GH release. Bagno et al. (2015) demonstrated that GHRH agonist treatment in a porcine model of ischemic cardiomyopathy reduced infarct scar mass, cardiomyocyte apoptosis, and inflammation while increasing angiogenesis and capillary density (Bagno et al., 2015).
Kanashiro-Takeuchi et al. (2015) confirmed direct cardiac GHRH-R activation as a therapeutic target for heart failure post-MI, independent of systemic GH/IGF-1 elevation (Kanashiro-Takeuchi et al., 2015).
Age-Related GH Decline (Somatopause)
GH secretion declines approximately 14% per decade after age 30, primarily due to reduced GHRH release and increased somatostatin tone. This "somatopause" contributes to age-related changes in body composition (increased adiposity, decreased muscle mass), bone density loss, and reduced tissue repair capacity (Corpas et al., 1993).
GHRH administration can partially restore youthful GH secretion in elderly individuals, demonstrating that the pituitary retains GH secretory capacity — the deficit is hypothalamic, not pituitary. This observation underpins the rationale for using GHRH analogues (sermorelin, CJC-1295, tesamorelin) for age-related GH insufficiency rather than direct GH replacement.
Growth Disorders
GHRH or its analogues are used diagnostically to assess pituitary GH reserve. The GHRH stimulation test differentiates hypothalamic from pituitary causes of GH deficiency — patients with hypothalamic dysfunction respond to exogenous GHRH, while those with pituitary failure do not. This test guided the development of sermorelin (Geref) as an FDA-approved diagnostic tool.
Anti-Cancer Properties
Paradoxically, while GHRH stimulates GH (which can promote tumor growth via IGF-1), GHRH antagonists have shown anti-tumor activity in multiple cancer models. However, GHRH agonists themselves have not shown tumor-promoting effects in published studies and may have direct anti-apoptotic effects on normal tissue that differ from their effects on malignant cells.
GHRH as a growth hormone secretagogue
Growth hormone-releasing hormone (GHRH) is the hypothalamic peptide that stimulates pituitary somatotrophs to secrete GH. The shortest fully active fragment, GHRH(1-29) or sermorelin, retains full receptor activity and was approved both as a diagnostic provocative agent and, historically, as a pediatric GH-deficiency therapy (Geref). Unlike exogenous GH, it preserves physiologic pulsatile secretion and negative feedback.
- GHRH(1-29)/sermorelin stimulates endogenous pulsatile GH release
- Approved for diagnosis and pediatric treatment of GH deficiency
- Preserves physiologic feedback versus direct GH replacement
Safety Profile
Native GHRH and its analogues have favorable safety profiles due to the preservation of physiological feedback mechanisms. The main advantage over exogenous GH is that GHRH-stimulated GH release cannot easily reach dangerous supraphysiological levels — somatostatin feedback limits the response. Side effects of GHRH agonists are generally mild: injection site reactions, transient facial flushing, and occasional headache. Theoretical concerns about GH/IGF-1 axis stimulation in the context of malignancy apply to all GH-promoting interventions. No significant long-term safety signals have emerged from decades of sermorelin and tesamorelin clinical use.
Pharmacokinetic Profile
GHRH (Growth Hormone Releasing Hormone) — Pharmacokinetic Curve
Intravenous (diagnostic), Subcutaneous (research)Quick Start
- Route
- Intravenous (diagnostic), Subcutaneous (research)
Molecular Structure
- Formula
- C215H358N72O66S
- Weight
- 5040.4 Da
- CAS
- 9034-39-3
Research Indications
Approved Indications
GHRH (as sermorelin, GHRH 1-29) stimulates pituitary GH release and is used as a diagnostic provocative agent.
Sermorelin (Geref) was FDA-approved to increase height velocity in children with idiopathic GH deficiency; later discontinued for commercial reasons.
Investigational / Off-label
GHRH analogues studied to raise endogenous GH pulsatility for body composition and sleep; clinical benefit for anti-aging not established.
Research Protocols
oral
- Development of oral GHRH analogues with improved stability (currently all require injection).
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| HIV lipodystrophy | 1 µg | Per protocol | — |
| General Research Protocol | 0.2-1.0 mg | Daily | — |
| Clinical research protocols | 1-10 µg | Per protocol | — |
intravenous Injection
Administered via intravenous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| HIV lipodystrophy | 1 µg | Per protocol | — |
| General Research Protocol | 0.2-1.0 mg | Daily | — |
| Clinical research protocols | 1-10 µg | Per protocol | — |
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Diagnostic (GHRH stimulation test) | 1 µg | Per protocol | — |
| Therapeutic (sermorelin) | 0.2-1.0 mg | Daily | — |
| Research (native GHRH) | 1-10 µg | Per protocol | — |
Interactions
Peptide Interactions
GH pulses are maximized when GHRH stimulation coincides with somatostatin nadir (troughs). Bedtime dosing of GHRH analogues leverages natural somatostatin withdrawal during early sleep.
What to Expect
What to Expect
Rapid onset expected; half-life of ~7-10 minutes (native form) indicates fast-acting pharmacokinetics
GH measured at baseline and 15, 30, 45, 60 minutes post-injection.
Due to short half-life (~7-10 minutes (native form)), effects are expected per-dose; consistent daily administration maintains therapeutic levels
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
- Multiple peer-reviewed studies available
Caution
- Injection site reactions reported
Frequently Asked Questions
References (10)
- [1]Guillemin R et al Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly Science (1982)
- [2]Rivier J et al Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour Nature (1982)
- [3]Ling N et al Synthesis and in vivo bioactivity of human growth hormone-releasing factor analogs Biochem Biophys Res Commun (1984)
- [4]Veldhuis JD et al Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man J Clin Endocrinol Metab (1995)
- [6]Bagno LL et al Growth hormone-releasing hormone agonists reduce myocardial infarct scar in swine with subacute ischemic cardiomyopathy J Am Heart Assoc (2015)
- [5]
- [7]Kanashiro-Takeuchi RM et al New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor Oncotarget (2015)
- [8]Tang S et al Interactions between GHRH and GABAARs in the brains of patients with epilepsy and in animal models of epilepsy Sci Rep (2017)
- [9]Geref International Study Group Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy Journal of Clinical Endocrinology & Metabolism (1996)
→ GHRH(1-29)/sermorelin 30 mcg/kg/day increased mean height velocity from 4.1 to 8.0 cm/yr in GH-deficient children.
- [10]Prakash A, Goa KL Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs (1999)
→ Reviews GHRH(1-29)/sermorelin as an approved secretagogue for diagnosing and treating pediatric GH deficiency.
GHRELIN
Ghrelin is a 28-amino-acid peptide hormone discovered in 1999 by Kojima et al. as the endogenous ligand for the growth hormone secretagogue receptor type 1a (GH
GHRP-1
GHRP-1 (Growth Hormone Releasing Peptide-1) is a synthetic hexapeptide and the first growth hormone secretagogue discovered by Cyril Bowers in the 1970s-1980s.